CMS: HealthCare.gov enrollment hits 1.6M in 2 weeks | Trump to roll out 2 final rules to lower drug prices | House bill closes Orphan Drug Act loophole
November 20, 2020
FOLLOW PCMA ON TWITTER Twitter
PCMA SmartBrief
News for the PBM IndustrySIGN UP ⋅   SHARE ⋅   ARCHIVE
ADVERTISEMENT
Featured Story
The latest figures from the CMS show that 1.6 million consumers signed up for health coverage through the federally run exchange in the first two weeks of open enrollment this year. Among this year's enrollees, 343,628 are new to the exchange.
Full Story: FierceHealthcare (11/19) 
LinkedIn Twitter Facebook Email
Legislative & Regulatory News
The Trump administration plans to release two final rules on prescription drugs, according to a senior administration official. One would ban drug rebates in Medicare, and the other would align prices paid by Medicare for certain drugs with those paid in other countries.
Full Story: The Wall Street Journal (tiered subscription model) (11/19),  MedPage Today (free registration) (11/21) 
LinkedIn Twitter Facebook Email
Drug Industry Spotlight
The House unanimously passed a bill that would require drugmakers seeking an orphan drug designation to demonstrate that they would be unable to recover R&D costs through US sales within 12 years. Drugmakers have been accused of using a loophole in the Orphan Drug Act that allows them to seek orphan designation for existing drugs.
Full Story: FiercePharma (11/19) 
LinkedIn Twitter Facebook Email
The FDA has released 21 revised and 13 new product-specific draft guidelines designed to promote the development of generic drugs, bringing the total number of such guidelines issued by the agency to 1,974. The guidelines explain the FDA's expectations for the studies required to prove the equivalence of a generic drug to a reference-listed drug.
Full Story: Regulatory Focus (11/18) 
LinkedIn Twitter Facebook Email
The World Health Organization does not recommend the use of Gilead Sciences' antiviral drug remdesivir for hospitalized patients with COVID-19, regardless of severity, "because there is currently no evidence that it improves survival or the need for ventilation," the WHO's Guideline Development Group said in a statement. Meanwhile, the FDA granted emergency use authorization for a combination of remdesivir and baricitinib for hospitalized patients with COVID-19 who need supplemental oxygen or who are on a ventilator or receiving extracorporeal membrane oxygenation.
Full Story: Regulatory Focus (11/19) 
LinkedIn Twitter Facebook Email
ADVERTISEMENT
Live and let live, be and let be/Hear and let hear, see and let see
Cole Porter,
composer, songwriter
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT PCMA:
Upcoming PCMA Events  |    PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
ADVERTISEMENT
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004